Clinical Significance of Sod2 and Gstp1 Gene Polymorphisms in Chinese Patients with Gastric Cancer

Zhi Xu,Haixia Zhu,John M. Luk,Dongmei Wu,Dongying Gu,Weida Gong,Yongfei Tan,Jianwei Zhou,Jinhai Tang,Zhengdong Zhang,Meilin Wang,Jinfei Chen
DOI: https://doi.org/10.1002/cncr.27599
IF: 6.9209
2012-01-01
Cancer
Abstract:AbstractBACKGROUND:Excessive reactive oxygen species (ROS) accumulation is a common phenomenon in carcinogenesis. However, the rationale behind ROS involvement in gastric cancer is unclear. In this study, the authors investigated the clinical significance of the single nucleotide polymorphisms (SNPs) of 2 ROS metabolic process‐related genes: superoxide dismutase 2 (SOD2) and glutathione S‐transferase π (GSTP1).METHODS:In total of 929 patients with gastric cancer who had definitive clinicopathologic and follow‐up data were collected. SOD2 reference SNP 4880 (rs4880) and GSTP1 rs1695 genotyping were examined in DNA samples extracted from paraffin‐embedded tumor tissue. Association of the 2 SNPs with each clinicopathologic feature was analyzed using the Pearson chi‐square test and the independent Student t test. Gastric cancer‐specific overall survival was analyzed using Kaplan‐Meier curves and log‐rank tests. Multivariate Cox regression analyses of these SNPs also were performed.RESULTS:The SOD2 rs4880 CT + CC genotypes were significantly associated with a high level of lymph node metastasis (P = .023), whereas the GSTP1 rs1695 GA + GG genotypes were significantly associated with larger tumor size (>5 cm long; P = .048). Kaplan‐Meier and Cox regression data indicated that the SOD2 rs4880 CT + CC genotypes alone (hazard ratio, 1.299; 95% confidence interval, 1.053‐1.603; P = .015) and the GSTP1 rs1695 GA + GG combined genotypes (hazard ratio, 1.496; 95% CI, 1.078‐2.074; P = .016) were independent predictors for overall survival.CONCLUSIONS:The current data, based on a large cohort (n = 929) of Chinese patients with gastric cancer, suggested that the presence of SOD2 rs4880 and GSTP1 rs1695 genotypes may contribute to cancer progression as well as tumor aggressiveness. The components of ROS metabolism pathways may be potential therapeutic targets for this aggressive malignancy. Cancer 2012. © 2012 American Cancer Society.
What problem does this paper attempt to address?